Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Alnylam buys Sirna from Merck for $186mm up front, plus earn-outs

Executive Summary

Alnylam Inc. (RNAi therapeutics for genetic diseases) acquired Merck & Co. Inc.’s Sirna Therapeutics Inc. RNAi division for $186mm up front, plus earn-outs and royalties.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Earnout
    • Full Acquisition
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies

Advertisement
UsernamePublicRestriction

Register